We report the safety and efficacy of OCU400 gene modifier therapy from the phase 1/2 clinical trial for NR2E3 and RHO associated RP (NCT05203939). Methods : The multicenter phase 1/2 open-label trial was a 3+3 dose escalation and dose expansion study. Participants included adults with ...
Ocugen, Inc. today announced that the Data Safety and Monitoring Board (DSMB) for the OCU400 clinical trial recently convened and established high dose as the maximum tolerable dose (MTD) in the dose-escalation phase of the study. Continued Po...